A peer-reviewed account of the interim results of the Oxford AstraZeneca Covid-19 vaccine (ChAdOx1) trials has appeared as an article in The Lancet . 23,848 people took part. Analysis of efficacy was based on weekly self-administered postal PCR swab tests in the UK arm of the trial. Altogether 30 participants who had received the vaccine and 101 who received the control had detectable Covid-19. 10 participants were hospitalised, none of them having received the vaccine, and of them one died.